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Overwhelming evidence suggests that negative urgency is robustly associated with rash, 
ill-advised behavior, and this trait may hamper attempts to treat patients with substance 
use disorder. Research applying negative urgency to clinical treatment settings has 
been limited, in part, due to the absence of an objective, behavioral, and translational 
model of negative urgency. We suggest that development of such a model will allow 
for determination of prime neurological and physiological treatment targets, the testing 
of treatment effectiveness in the preclinical and the clinical laboratory, and, ultimately, 
improvement in negative-urgency-related treatment response and effectiveness. In the 
current paper, we review the literature on measurement of negative urgency and discuss 
limitations of current attempts to assess this trait in human models. Then, we review 
the limited research on animal models of negative urgency and make suggestions for 
some promising models that could lead to a translational measurement model. Finally, 
we discuss the importance of applying objective, behavioral, and translational models 
of negative urgency, especially those that are easily administered in both animals and 
humans, to treatment development and testing and make suggestions on necessary 
future work in this field. Given that negative urgency is a transdiagnostic risk factor that 
impedes treatment success, the impact of this work could be large in reducing client 
suffering and societal costs.
Keywords: negative urgency, animal model, delay discounting, Impulsive behavior, internalizing disorder, 
transitional, UPPS Impulsive Behavior Scale
INTRODUCTION
Negative urgency is an impulsive personality trait reflecting the tendency to act rashly when 
experiencing extreme negative emotional states, included in the UPPS-P Model of Impulsive 
Behavior (1, 2). Overwhelming evidence suggests that negative urgency is robustly associated with 
rash, ill-advised behavior, and this trait may hamper attempts to treat patients with substance use 
disorder [e.g., Refs. (3, 4)]. However, a systematic investigation of negative urgency in the context of 
treatment has been limited, in part, due to the lack of a valid objective, behavioral, and translational 
model of negative urgency. The goal of the current paper is to review the current human and animal 
approaches to the measurement of negative urgency and to make suggestions on how an objective 
translational model could be developed. We review the existing literature and make suggestions for 
prime models that can be explored as translational approaches in negative urgency. We also review the 
neural and psychopharmacological correlates of negative urgency, suggesting potential novel targets 
of intervention within a translational model. We suggest that the development of a translational 
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model easily administered in animals and human would allow for 
better characterization of the neuroscientific correlates of negative 
urgency, determination of prime neurological and physiological 
treatment targets, and the validation of an objective measure of 
treatment effectiveness in the preclinical and clinical laboratory.
NEGATIVE URGENCY IN THE BROADER 
CONSTRUCT OF IMPULSIVITY AND 
PERSONALITY
Impulsivity is broadly defined as traits and behaviors that 
predispose individuals to rash action (or ill-advised inaction) 
(5–7). The UPPS-P model integrated existing personality-based 
measures of impulsivity into five traits, using the Five-Factor 
Model as a theoretical framework. The five traits include negative 
urgency, positive urgency (i.e., a tendency to act rashly in response 
to extreme positive emotional states), lack of premeditation (i.e., 
a tendency to act without thinking), lack of perseverance (i.e., 
an inability to stay focused on a task), and sensation seeking 
(i.e., tendency to seek novel and exciting experiences). These 
traits are best described as separate, though related, tendencies 
toward rash action (8). Research supports a multidimensional 
nature of impulsivity, and extensions of the UPPS-P model have 
been suggested (9). There is increasing consensus that impulsive 
personality consists of traits that are affect-free and traits that 
have a strong affective component (9, 10). The distinction 
between affect-based and affect-free impulsigenic traits is further 
supported by the fact that they share little common variance 
(0–13%) (10).
Negative urgency is well placed in the personality literature. 
It shares conceptual overlap with the Impulsiveness facet of the 
NEO-PI-R (11); however, a factor analysis by Peterson and Smith 
(2008) found that negative urgency loaded onto the Neuroticism, 
Conscientiousness, and Agreeableness factors, suggesting that 
negative urgency is not represented by one domain or facet of 
the NEO-PI-R, but rather assesses a trait characterized by high 
distress, low conscientiousness, and low agreeableness (2). Some 
have suggested that negative urgency (along with the positive 
mood variant of positive urgency) is quite similar to one of the 
two higher-order dimensions of the Five-Factor Model (alpha, 
representing high levels of emotional instability, disagreeableness, 
and disinhibition) (12, 13).
What differentiates negative urgency from other constructs 
pertaining to responses to emotions, such as emotion regulation 
and emotional lability, is that it reflects a disposition to reflexive 
reactions in response to intense negative emotion. Emotion 
regulation involves efforts, either reflexive or effortful, to modify 
the intensity of the experienced emotion that varies across 
situations and across time, and emotion dysregulation can occur 
in the absence of intense emotion (14, 15). Negative urgency 
captures the between-person variability in the capacity to control 
intense emotion-driven urges (10). Effects of negative urgency are 
not explained by additive or interactive combinations of negative 
affective traits (e.g., neuroticism, emotional lability) combined 
with general disinhibition (2, 8). Similarly, negative urgency is 
only moderately correlated with measures of emotion regulation, 
which signifies that these are related, but separate, constructs 
with distinct contributions to psychopathology (16). In fact, 
the majority of the reliable variance in negative urgency is not 
explained by other related traits (2).
NEGATIVE URGENCY AS  
A TRANSDIAGNOSTIC RISK  
AND TREATMENT FACTOR
Accumulating evidence suggests that negative urgency is one of the 
most robust predictors of a wide range of maladaptive behaviors 
and psychopathology, including alcohol use and dependence 
(3, 5, 17, 18), tobacco use and dependence (19–21), and 
problematic cannabis use (22–24). The fact that negative urgency 
developmentally precedes substance use and addictive disorders 
(25, 26) indicates that negative urgency is likely a contributor to 
the development and maintenance of addictive disorders. This is 
further bolstered by empirical evidence showing that decreases 
in impulsivity are associated with decreases in substance use 
across the lifespan (27). This accumulating evidence supports the 
notion that negative urgency is a transdiagnostic endophenotype 
for problematic levels of behaviors associated with risk (28). This 
includes not only addictive behaviors, but also disorders highly 
comorbid with these conditions, such as depression, anxiety, and 
bipolar disorders (5, 28, 29). Negative urgency is represented in 
broad diagnostic criteria of the Diagnostic and Statistical Manual 
of Mental Disorders, Fifth Edition (DSM-5) (29).
Despite the substantial amount of research implicating 
negative urgency in the development and maintenance of 
addictive behaviors, only a small body of empirical work has 
systematically studied its application to treatment (29, 30). 
There are no specific behavioral or pharmacological treatments 
for negative urgency, although some have been suggested (31). 
A meta-analysis conducted by Hershberger et al. (30) examined 
the effect of negative urgency on substance use disorder 
psychotherapy outcomes and how this trait changes during 
treatment. The findings showed that increased levels of negative 
urgency at baseline are related with poorer treatment outcomes, 
suggesting that this trait potentially inhibits substance use 
symptom improvement (30). Additionally, the authors identified 
only small decreases in negative urgency (g = −0.25) from the 
beginning to the end of treatment. This suggests that current 
substance use treatments are not changing negative urgency 
notably, which increases the risk for subsequent substance use 
re-initiation or relapse (30). They explain one way in which 
negative urgency lowers treatment efficacy: Most existing 
therapies for addictive disorders are focused on the modification 
of proximal factors related to addiction, such as substance use 
motives or environments that facilitate use, rather than the distal 
factors, such as negative urgency, that underlie them (32, 33). For 
example, negative urgency is a predictor of the development of 
substance use motives (34) and likely contributes to individuals 
seeking out and selecting environments that facilitate use, 
consistent with personality–environment transaction theories (35). 
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Although addressing proximal risk factors of addiction 
might improve current symptoms, if distal risk factors remain 
unchanged, relapse or treatment nonresponse becomes more 
likely (29), as the distal factors can impart risk independent 
of the modified proximal factor. The authors suggest that the 
integration of negative urgency in case conceptualization, 
treatment planning, and goal setting would significantly improve 
substance use treatment outcomes (30).
Although negative urgency-targeted interventions have not 
been systematically developed or investigated, there is promising 
evidence for their potential success. Zapolski et al. (31) provided 
recommendations for strategies to target negative urgency in 
treatment. Their recommended strategies include training in 
emotion regulation, distress tolerance, interpersonal effectiveness, 
training in modifying emotional reactions based on the context, 
relaxation techniques, identification of precipitating events and 
triggers to emotional reactivity and use of adaptive alternatives, 
and the use of medications, such as selective serotonin reuptake 
inhibitors (31, 36). Many of these strategies have been successfully 
incorporated in several clinical interventions in different contexts, 
including substance use, and their effectiveness has been tested 
and supported (5, 26, 36–40) with some exceptions (41, 42). 
Because negative urgency increases the risk of a wide range 
of addictive behaviors and other clinical disorders, negative-
urgency-targeted interventions could have wide and broad 
benefit. Additionally, such interventions are easily adopted by 
addiction medicine practitioners and would improve their daily 
practice in prevention, treatment, and rehabilitation of addictive 
disorders and accompanying conditions.
We propose that an important and viable long-term goal is 
to design and test pharmacological, psychological, behavioral, 
and physiological treatments that specifically aim to reduce 
negative urgency. This would allow the application of these 
treatment strategies transdiagnostically, which would be fruitful 
to reduce not only the target disorder (e.g., alcohol use disorder), 
but also maladaptive coping related to comorbid disorders 
(e.g., depression). Thus, one intervention could be effective for 
treatment of multiple disorders or behaviors. In the current 
paper, we focus specifically on the role of negative urgency in 
addictive disorders, although the implications would likely apply 
to any disorder in which negative urgency is implicated (29).
CURRENT MEASUREMENT OF NEGATIVE 
URGENCY IN HUMANS
Negative urgency is most commonly measured using the UPPS-P 
Impulsive Behavior Scale. The UPPS-P is a 59-item self-report 
questionnaire originally created by Whiteside and Lynam (1) 
with four subscales (negative urgency, lack of premeditation, lack 
of perseverance, and sensation seeking). The positive urgency 
subscale was added later (43, 44). Individuals rate their general 
tendencies on a four-point scale from Agree Strongly to Disagree 
Strongly. Individual item scores are reverse coded (as needed) 
and averaged together to approximate a mean level of each 
trait, with higher scores indicating higher levels of rash action. 
The negative urgency subscale includes items assessing the 
disposition of respondents to act without careful consideration 
of the consequences when faced with negative affect. Example 
items for the scale include “When I feel bad, I will often do things 
I later regret in order to make myself feel better now” and “When 
I am upset, I often act without thinking.” The UPPS-P has been 
shown to produce valid and reliable data across men and women, 
different age groups, and clinical and community samples 
(43, 45–47).
Although there are no behavioral tasks developed specifically 
to assess negative urgency, there are many behavioral tasks 
measuring state-like rash action in general (48, 49). Both self-
report and behavioral task measures of rash action are strongly 
correlated with risky behaviors, but research has shown little 
overlap between these two types of measures. A meta-analysis 
conducted by Cyders and Coskunpinar (48) found that effect 
sizes for the relationship between self-report and behavioral 
task measures of rash action are small, ranging from r = 0.097 to 
0.134, suggesting that at least 99% of the variance between these 
types of measures is unshared. This indicates that self-report 
and behavioral measures of rash action assess complementary, 
but separate, constructs. In some ways, this lack of overlap is not 
surprising, as these different task domains assess separate aspects 
of rash action. Self-report measures likely represent stable 
tendencies toward general behaviors (trait-like impulsivity) 
reflecting predominately emotional/motivational mechanisms of 
rash action, whereas behavioral tasks are more likely snapshots of 
behavior (state-like impulsivity) in response to stimuli, reflecting 
predominately cognitive mechanisms of rash action (9).
Self-report measurement of negative urgency has important 
strengths in the context of psychopathology. First, it has content 
and ecological validity as it reflects the individuals’ subjective 
experience of patterns of thoughts, emotions, and behaviors in 
daily life, which can easily be generalized to the real world (50). 
Second, it has strong face validity, in that questions and results 
can be easily interpreted without making assumptions since they 
are based on direct and clear questions to the respondents (29, 
48). Finally, it is inexpensive and easy to administer to a large 
group of people (48). However, this type of assessment has 
some limitations that make it less ideal in designing or testing 
the efficacy of treatments. Self-report measurement is limited 
by self-awareness, openness, and social desirability (48, 51), 
making the assessment only as good as what a person knows and 
is willing to report about the self. For example, in a clinical trial, 
individuals might not report on less socially desirable aspects of 
the self, and thus baseline levels might be underestimates of the 
true level of negative urgency, making measuring change over 
the trial more difficult. Relatedly, measuring negative urgency 
repeatedly in short succession might lead to participant fatigue 
or might influence an individual’s responses in undue ways, 
further contributing to error in the measurement. For example, 
in a clinical trial, individuals might report a reduction in negative 
urgency after treatment, because they assume such a reduction is 
expected and not due to any true changes in the trait in response 
to treatment. Additionally, because the UPPS-P evaluates general 
tendencies, changes that do occur in shorter time frames might 
not be accurately assessed via this measure (i.e., it is not designed 
to assess shorter fluctuations in behavior). Finally, self-report 
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measures are difficult to translate into animal models. Behavioral 
tasks designed to measure the behavioral expression of negative 
urgency in lab settings would be an excellent complementary 
approach to address these limitations and to better design and 
assess treatment effectiveness.
ANIMAL MODELS OF NEGATIVE 
URGENCY
The use of animal models would greatly enhance the capability 
to deconstruct possible underlying neural mechanisms of 
negative urgency and allow for greater manipulation of testing 
variables to determine new therapeutic targets. There are 
numerous papers describing external validity, including the 
specific criteria animal models must meet and how different 
facets of external validity simulate conditions, neurobiology, 
and behavior seen in clinical populations (e.g., 52–55). 
The earliest characterization of these criteria included the 
requirement for animal models to demonstrate the same 
etiology, symptoms, response to treatment, and biochemistry 
seen in human populations (54). These criteria were the 
foundation for decades of work establishing a well-defined 
framework for animal models. The traditional framework, 
proposed by Willner (55), included three types of validity: 
predictive validity (i.e., the model predicts some criterion 
of interest), face validity (i.e., the model looks similar to the 
human condition), and construct validity (i.e., the animal 
model measures what is intended to measure) (55). Expansions 
and modifications of these criteria provide a more granular 
method for establishing reliable, translatable animal models, 
taking into account several factors that represent critical 
points for similarity. Geyer and Markou (53) emphasized the 
additional importance of etiological validity (i.e., the model 
has the same etiology as human condition) and convergent/
discriminant validity (i.e., the model is associated with other 
related models but unrelated to models that are disparate 
with the underlying condition). Belzung and Lemoine (52) 
further emphasized induction validity (i.e., etiological effects 
on observable behaviors in animals have similar effects in 
humans) and remission validity (i.e., similarity in response to 
treatment across animal and human conditions).
Any animal model of negative urgency must fulfill these 
validity requirements; we evaluate existing and potential models 
in terms of these criteria (Table 1). For the sake of simplicity, we 
have not included every measure, but rather those we believe most 
strictly comply to a model of negative urgency. We also highlight 
the types of validity each model satisfies, where applicable, which 
aids in determining translatability.
At present, studies investigating negative urgency in animals 
are sparse. One proposed method for generating negative 
urgency (utilized in both animal and human models) involves 
unexpected reward omission (56–58). In one study, humans or 
rats were trained to perform an operant task (button pressing 
or lever pressing, respectively) and were rewarded with either 
money or a food pellet, respectively (56). Increases in response 
rates and decreases in response latencies were dependent 
variables constituting measures of negative urgency. This task 
has many strengths, including that it can and has been applied 
across human and animal models and that it appears to have 
adequate predictive and face validity for the emotional change. 
The task is especially analogous in clinical and preclinical 
administration (56); however, this task lacks the “rash action” 
component necessary to accurately assess negative urgency. For 
the model to have good external validity, there must be some 
procedure in place to assess the effect of this induced negative 
urgency on impulsive behavior. In short, this model does not 
provide any negative consequences of impulsive behavior 
generated through negative affect. Therefore, although this task 
shows some promise, further research is required for better, 
more representative models.
SUGGESTIONS FOR OBJECTIVE 
TRANSLATIONAL MODELS OF  
NEGATIVE URGENCY
Affective State
Clinical designs for incitement of negative affect in humans 
include the International Affective Picture System (IAPS), 
the Paced Auditory Serial Addition Test (PASAT), and 
social rejection, although there are no analogous methods 
in animal models (59, 60). The IAPS involves presentation of 
positive, neutral, or negative images (61). Numerous studies 
have shown that the administration of the IAPS is effective in 
producing transient negative emotion with resultant changes 
in brain activity or behavior (62–66). However, none of these 
studies has demonstrated increased impulsive, rash behavior 
associated with that negative affect. The PASAT is a procedure 
in which subjects must serially add a quickly vocalized list of 
numbers and is a demonstrated lab-induced stressor (67). 
Implementation of a social rejection protocol has generated 
changes in response inhibition during a Go/No-Go task (64, 68), 
thus linking negative affect with rash action. A meta-analysis 
by Westerman (69) outlines numerous other mood induction 
paradigms (including video clips, writing, etc). and describes the 
strengths and drawbacks of each. For example, the Imagination 
mood induction procedure requires the subject to imagine an 
emotion-laden experience from their past, and the Velten mood 
induction procedure requires the participants to make negative 
self-references (69). Unfortunately, these methods are not 
conducive to reproduction with animal models.
Although these findings suggest usefulness of these methods 
in humans, translatability to animals is questionable at best. 
There is no comparable method to many of these procedures 
(IAPS, PASAT, Imagination, Velten) in preclinical studies. 
While social isolation models in rodents can elicit behavioral 
modifications, these are typically utilized to produce depressive 
states and may instigate neurobiological alterations that have 
little connection to impulsivity and may hinder the ability to 
interpret results (54, 70, 71). For greatest translatability, the 
methods by which negative urgency are elicited should be as 
similar as possible in human and animal subjects.
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Currently, there are several animal models capable of inducing 
stress, anxiety, and depression, such as restraint stress, foot 
shock, and the forced swim test (72–75). Many of these suffer 
from limited translatability to clinical models, due to ethical 
or feasibility restraints. Additionally, these models typically 
result in long-term effects (including downstream effects on 
neurotransmitter systems), in addition to immediate, negative 
states. For an animal model to have good face and etiological 
validity, there must be some instigating event that engenders a 
transitory negative state without conferring semi-permanent 
or permanent change. Given the effects of corticosterone on 
numerous brain regions, including the hippocampus (76, 77), 
the task should avoid chronic stressors and focus on events 
that primarily lead to depressive-like states. Additionally, it is 
important to limit exposure to the negative stimulus to avoid 
creation of a disposition to depression often seen after repeated 
administration (78). This distinction permits researchers to 
narrow investigations to discrete elicited state-like behavior 
rather than long term, trait-like behavior.
Impulsive Choice
Delay discounting is based on the premise that reinforcer 
influence on behavior decreases as a function of the delay to its 
delivery (79). In one version of this task, the adjusting amounts 
version, subjects complete several trials in which they must 
choose between a small, immediate reward and a larger, delayed 
reward and every choice of the immediate reinforcer decreases 
the amount of reinforcer available upon choice of the immediate 
reinforcer on the next trial (80, 81). In this manner, repeated 
choice of the immediate reinforcer results in overall suboptimal 
levels of reinforcer across the session. Although delay discounting 
is typically thought to assess levels of cognitive impulsivity (82), 
the design of the task is such that impulsive-like responding 
is rewarded immediately (immediate reinforcer) and is then 
consequently paired with decrease in immediate reinforcer 
volume. Through manipulation of the length of the delay to the 
larger reward and the use of the hyperbolic discounting equation, 
we are able to generate a “discounting curve” that describes the 
steepness or “impulsivity” of each individual. This curve can be 
TABLE 1 | Methods for induction of negative affect and measurement of impulsive responding. This table lists several possible suggestions for induction of negative 
affect in animals and humans and impulsivity assessment. It also outlines which types of validity (which describes translatability) are fulfilled with each task. NEO-PI-R: 
NEO Personality Inventory, revised; IAPS: International Affective Picture System; na: no available data.
TASK APPLICABLE  
IN HUMANS
APPLICABLE  
IN ANIMALS
TYPES OF VALIDITY
FACE CONSTRUCT ETIOLOGICAL CONVERGENT INDUCTION REMISSION
INDUCTION OF 
NEGATIVE AFFFECT
REWARD OMMISSION 
TASK
+ + + + + + + na
IAPS +
Paced Auditory Serial 
Addition Test
+
IMAGINATION Mood 
Induction Procedure
+
VELTEN Mood Induction 
Procedure
+
SOCIAL REJECTION 
(humans)
+
SOCIAL ISOLATION 
(animals)
+ + + na
FOOT SHOCK + + na
FOOD DEPRIVATION + + + na
ACUTE RESTRAINT 
STRESS
+ + + na
MEASURES OF IMPULSIVITY
DELAY DISCOUNTING + + + + + + + +
GO/NO-GO + + + + + + + +
STOP SIGNAL + + + + + + + na
CONTINUOUS 
PERFORMANCE TASK
+ + + + + + + na
BALLOON ANALOGUE 
RISK TASK
+ + na
ERIKSEN FLANKER 
TASK
+
SELF-REPORT MEASURES 
UPPS-P + +
NEO-PI-R (Impulsiveness 
facet)
+ +
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thought of as a measure of how long the subject is willing to wait 
for a specific reward, a measure of “cognitive impulsivity.”
Previous work has demonstrated the translatability of delay 
discounting. The delay discounting model has considerable face 
validity (52). The basic premise is identical in both human and 
animal models, particularly in the Experiential Discounting 
Task for humans, which requires the participant to experience 
the delay during the task, rather than afterwards, eliminating the 
need for the subject to “imagine” the delay while continuing to 
respond (83). In the animal version, subjects are also required 
to experience the delay during the session. Furthermore, one of 
the proposed mechanisms of external validity is the requirement 
that the task must measure the same changes in behavior upon 
treatment (remission validity) (52). Although this version of delay 
discounting most closely resembles the version administered in 
animals, there are possible limitations in test–retest reliability 
and conflating the delay and probability of receiving reward (84). 
A more common administration (the adjusting amounts version) 
involves presenting a delayed choice that will be accessible at some 
point in the future rather than implementing the delay during 
the task itself. The adjusting amounts version is also efficient 
at generating discounting curves and there is no demonstrable 
difference in effect between delayed rewards during the task and 
those imagined in the future (85). The animal version of delay 
discounting described here is accurate enough to detect the same 
decreases in impulsivity after stimulant (methamphetamine/
amphetamine) administration observed in clinical applications 
(86–91). Given the demonstrated ability of the delay discounting 
task to evaluate changes in impulsive, rash behavior, and the 
translatability of those results, it may provide a valid mechanism 
to analyze behavior motivated by a negative emotional state.
Impulsive Action
In the Go/No-Go task, the subject is required to respond on a 
specified manipulandum upon presentation of some stimulus 
during “Go” trials and must inhibit that response upon presentation 
of some stimulus during “No-Go” trials (92, 93). This method is 
used to measure action restraint in a number of animal models of 
disease, including alcohol use disorder (94). A meta-analysis found 
a significant correlation between results on clinical applications 
of the task with self-report measures of negative urgency (48). A 
recent study examining the association between induced negative 
urgency and performance on the Go/No-Go task revealed that 
greater activation in brain regions involved in inhibitory processes 
was correlated with higher levels of urgency (64–66, 68). An 
investigation into the effects of social rejection on impulsivity found 
that subjects reporting higher levels of negative affect completed 
significantly fewer successful No-Go trials (95). There is also 
evidence that responding in the Go/No-Go task predicts relapse 
rates in abstinent alcoholics (96). Administration of this task in 
an animal model of negative urgency could pave the way toward 
understanding what neural correlates underlie this association.
Conclusions on Translational Tasks
In conclusion, although the literature on animal models of negative 
urgency is sparse, there are some interesting and promising 
attempts to model negative urgency preclinically. The very 
nature of negative urgency centers upon behavioral reactions to 
emotional states, suggesting an internalizing primary aspect of the 
trait that is integrated with an externalizing behavioral outcome. 
Therefore, any reliable, translatable model of negative urgency 
must include a method for inducing negative affect in addition to 
the demonstration of an externalizing behavior of some interest. 
Unfortunately, the design of preclinical models of internalizing 
affective disorders is inherently problematic. Emotional states, 
such as depression, are not easily represented in non-human 
subjects, which limits the ability to devise translational, behavioral 
measures (52, 78, 97–99). Any animal model seeking to evaluate 
affectivity must demonstrate the capacity not only to induce a 
specific emotional state, but also to effectively identify alterations 
in that state under manipulation. Since evaluating the subjective 
experiences of animals is difficult, this is a challenging prospect; 
however, the translatability of the model is necessary for the 
generation of meaningful results (52).
Ideally, the behavior evoked by the induction of negative 
affect should be immediately reinforcing, yet ultimately yield 
suboptimal results. Cyders and Smith (100) proposed that 
rash or ill-advised actions during times of negative arousal, 
such as consuming alcohol upon receipt of bad news, provide 
immediate relief, reinforcing the behavior (100). Alternatively, 
more adaptive coping mechanisms are not implemented, 
limiting the reinforcement of these responses. For example, 
then, engagement in repeated alcohol intake to alleviate negative 
affectivity is reinforced and the behavior becomes more frequent, 
despite being detrimental in the long term. The key in an animal 
model is to devise a task that provides an opportunity to access 
a preferred reward (food, sucrose, mating), paired with loss of 
a highly valued resource or punishment, such as excessive lever 
pressing, resulting in smaller amounts of reward over time.
NEURAL AND GENETIC CORRELATES OF 
NEGATIVE URGENCY AND POTENTIAL 
TREATMENT TARGETS
There are numerous excellent reviews outlining human brain 
structures and systems believed to contribute to the experience of 
negative urgency (2, 101) and other emotion-related constructs 
(9, 102–104). Given the implicit obstacles associated with 
neuroimaging in rodents and the lack of definitive homologous 
prefrontal regions in rodent brains, there has been limited 
information gleaned from animal neuroimaging studies.
Human Neuroimaging
Research concerning the neurobiology underlying negative 
urgency follows two primary tracts: structures and systems that 
represent bottom-up processing and structures and systems 
that are associated with top-down regulatory control. Regions 
representing bottom-up processing, such as the amygdala, 
have connections to regions regulating top-down control, 
including the orbitofrontal cortex (OFC), the ventral medial 
prefrontal cortex (vmPFC), and the dorsolateral PFC (dlPFC). 
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These connections constitute a reciprocal system by which both 
systems integrate to detect negative affect, determine the salience 
of that affect, and initiate or inhibit behavior in reaction (2). For 
instance, the amygdala is greatly involved with the experience 
of negative emotions (105) and projects to, and receives back 
projections from, the OFC (106). The OFC and its medial sector, 
the vmPFC, play a role in modulating emotion-based behavior 
and reactivity (105) and can inhibit behavior that is emotion-
based (107). The ability of top-down regulatory systems to 
control emotion-based behavior is essential for preservation 
of long-term goals. There is emerging evidence that negative 
urgency relates to variations in neural activity in these and other 
subcortical [ventral striatum (VST) and caudate nucleus (CAU)] 
and frontal (dlPFC) brain regions (57, 64, 68, 108, 109).
There is a wealth of information concerning the function of 
these brain regions from neuroimaging studies, implicating the 
association of various structures in negative-urgency-mediated 
ill-advised behaviors, particularly in alcohol use disorder 
populations and social drinkers. The insula (INS), which plays 
a role in emotional processing, shows greater activation during 
negative urgency in adolescent binge drinkers (110). The caudate 
(CAU) demonstrates greater activation in response to alcohol 
cues in social drinkers (64, 68). The mOFC/vmOFC, primarily 
engaged in evaluation of rewarding stimuli to determine action, 
is activated more strongly to alcohol odor cues, while activation 
of the lOFC, which evaluates punishing stimuli, was related to 
negative urgency in social drinkers (63). The PFC, particularly 
the dlPFC, is heavily recruited during cognitive tasks in subjects 
high in negative urgency (111, 112). Finally, the amygdala, which 
is specifically involved in processing negative emotions (113) 
and is an important hub in negative urgency (101), shows greater 
activation in response to negative mood images and during 
negative mood evaluation in cocaine users with personality 
disorders (114, 115). Taken together, these findings imply a 
dysregulation in this interconnected system of regions associated 
with emotional processing and emotion-based behavioral 
control, which is likely contributing to maladaptive actions in 
pathological populations.
Emerging evidence from functional connectivity studies 
indicates that these structures interact to direct emotional lability 
and drive behavior. Dysfunction in the vmPFC impacts its 
association with the amygdala, resulting in potentiated response 
to emotional cues (116). Non-treatment-seeking alcoholics have 
aberrant anterior insular cortex connectivity, a region associated 
with assignment of emotional states to interoceptive bodily stimuli 
(117). There is evidence of increased cortico-limbic connectivity 
in cocaine-dependent subjects, associated with emotion-based 
impulsivity (118). A model-free, resting-state study of alcohol-
dependent subjects found increased within-network connectivity 
in salience, orbitofrontal, and default mode networks and 
increased between-network connectivity associated with higher 
self-reported ratings of negative urgency (119). These findings 
indicate interconnected, functionally coupled sets of brain 
regions associated with emotional activation and responding, 
which must be better understood to further development of 
more targeted treatment strategies. There are numerous avenues 
for further exploration using connectivity tools, which would 
immeasurably enhance insight into underlying mechanisms of 
behavior. Unfortunately, neuroimaging techniques are inherently 
difficult to conduct in animal models and may be confounded by 
agents used to anesthetize subjects, limiting investigations at the 
preclinical level.
Human Neurotransmitter Systems
Function in many of the above brain regions is largely mediated by 
dopamine (DA) and serotonin (5HT) transmitter systems. These 
systems interact to influence emotion-based decision-making. 
Researchers have reported that low levels of 5HT are associated 
with greater incidences of rash or maladaptive behavior involving 
risk and increases in negative affect (120–125). Conversely, 
subjects with lower mono-amino oxidase, responsible for 
the breakdown of 5HT, display higher levels of aggression 
and negative urgency (126), which suggests that it may be the 
dysregulation of serotonin that influences emotional lability 
rather than simply a depletion. Interestingly, high 5HT levels in 
the PFC are correlated with socially adept behavior in monkeys 
(127), while low levels of 5HT in the anterior cingulate cortex 
are correlated with inhibited emotional regulation (124). It is 
important to note that these associations are receptor-dependent. 
The 5HT system is composed of several types of receptors and 
transporters, which may infer opposite effects upon activation. 
For instance, a reduction in 5HT available at 5HT2c and 5HT1a 
receptor sites increases likelihood of impulsive, rash behavior, 
while low 5HT at 5HT2a receptor sites reduces risky behavior 
(128, 129). This dichotomy in receptor effects is important when 
determining possible pharmacological treatments. Although 
5HT2c and 5HT1a receptors are more common, any prospective 
treatment targeting this system would be better served to attempt 
pharmacological effects specified for these receptors.
Alternatively, greater levels of DA activity are associated with 
a higher tendency to act (130), greater behavioral disinhibition 
(131), and greater reward-seeking and risk-taking behaviors 
(132, 133). DA is highly influential in the OFC–amygdala circuit 
(considered to be the “reward” circuit), particularly at D2 and D4 
receptor sites, and it is theorized that DA effects on rash action 
may stem from D2 activation decreasing the value of delayed 
rewards (134). A recent study evaluating DA availability using 
positron emission tomography (PET) found that increased levels 
of DA in the putamen were associated with greater levels of 
impulsivity on the delay discounting task (135). The DA system 
in the OFC–amygdala circuit is modulated by serotonergic input 
through both direct and indirect mechanisms (136, 137). 5HT 
systems that subsume information processing influence DA 
pathways that underlie approach behavior (120, 138); therefore, 
decreased 5HT levels would result in diminished suppression of 
rash, ill-advised behavior.
Human Genetics
Overall, it is well-established that behavior consistent with 
negative urgency is associated with depleted 5HT levels in the 
PFC and overactive DA in the OFC–amygdala circuit. There are 
a number of genetic polymorphisms possibly contributing to the 
imbalances observed in populations endorsing elevated negative 
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urgency. Certain alleles of the serotonin transporter gene 
(5HTTLPR) and DA receptor genes (DRD2, DRD3, and DRD4) 
have all been associated with fluctuations in 5HT and DA levels 
and, thus, frequency of emotion-based rash behaviors (139–144). 
Associations between DA and 5HT are also present in an animal 
model of negative urgency. Yates et al. found that increased 
DA transporter function in the nucleus accumbens and greater 
5HT transporter function in the OFC are mediated by higher 
exhibited negative urgency in a reward omission task (57). This 
neurobiological similarity highlights the usefulness of animal 
models to further elucidate the correlation between negative 
urgency and risky behavior, such as alcohol consumption.
There is limited information regarding the association between 
these neurotransmitter systems and negative urgency in alcohol 
use disorder populations. There are numerous lines of evidence 
indicating that decreased levels of 5HT are strongly associated 
with increased alcohol consumption and risk for future alcohol 
problems (145–147). One recent study reported that negative 
urgency (as measured by UPPS-P) mediated the relationship 
between alcohol abuse and genetically driven decreases in 5HT 
availability (148). In this study, higher polygenic 5HT scores 
(indicating lower 5HT function) were positively correlated with 
higher self-reported negative urgency and greater levels of alcohol 
consumption. At this time, there are no preclinical investigations 
evaluating the relationship between these transmitter systems, 
alcohol overconsumption, and negative urgency, although one 
study did report an increase in negative affect during cocaine 
withdrawal in rats in the reward omission task (58).
In addition to the influence of the DA and 5HT systems, there 
is evidence that polymorphisms of the GABRA2 gene, which 
codes for the GABAAa2 receptor, are also associated with both 
alcoholism risk and negative urgency (149). Villafuerte (150) 
identified an association between impulsiveness and alcoholism 
with genetic variants of the GABRA2 gene in a family strongly 
endorsing alcoholism (150). This same study reported that this 
association was mediated by activation during reward or loss. 
Further research uncovered that impulsiveness, particularly 
negative urgency, mediates the association between the GABRA2 
gene and alcoholism (151). In addition, lower levels of gamma-
Aminobutyric acid (GABA) in the dlPFC are correlated with 
greater reports of negative urgency (152). This region is implicated 
in the effortful control of behavior and is heavily activated 
during behavioral inhibition tasks in subjects high in negative 
urgency. Lack of GABA in this brain region may inhibit function, 
decreasing the ability of the dlPFC to efficiently regulate behavior.
Implications for Treatment
Taken together, these findings provide excellent opportunities for 
translation to animal models, with the ultimate goal of improving 
clinical treatment. Translation of negative urgency to preclinical 
models would improve treatment in three main ways.
First, it allows for more precise identification of the neural 
correlates of negative urgency in human neuroimaging studies. 
Examining these regions translationally allows for more precision 
in the identified regions, circuits, and neurotransmitter systems. 
For example, identified neural substrates mediating negative 
urgency may be manipulated in animal models, and support 
of those hypotheses would provide data suggesting potential 
mechanisms through which those substrates may be manipulated 
to aid in treatment. Thus, this would help determine if these brain 
correlates are simply associated with negative urgency or are a 
causal mechanism in these maladaptive behaviors. This could 
lead to novel neurological and physiological targets.
Relatedly, animal models provide a unique opportunity to 
further elucidate neural underpinnings of behavior through 
manipulation of genetic predispositions. There are several lines 
of mice and rats selectively bred to prefer alcohol, including 
alcohol-preferring rats, high alcohol-drinking rats, and high 
alcohol-preferring mice (153, 154). Behavioral models can 
be used to compare responding to negative urgency in these 
subjects to responding observed in low alcohol-preferring 
subjects. These methods have demonstrated the ability 
to identify behavioral characteristics inherited alongside 
the predilection to prefer and consume alcohol, including 
impulsive-like responding in a delay discounting task (81, 155). 
Furthermore, they increase understanding of contributions of 
specific brain regions, networks, and neurotransmitter systems 
on alcohol consumption and associated risky behavior (156–
160). Manipulation of brain region function in selectively bred 
animals through lesion studies, or neurotransmitter systems 
through pharmacological agents, grants researchers the ability 
to assess how each component affects behavior and determine 
what modifications may be employed to alter that behavior. 
Importantly, upon development of an animal model of negative 
urgency, researchers can better understand the relationship of 
negative affect and alcohol consumption. Although research 
implies that trait negative urgency contributes to the progression 
of alcohol use disorder, is it possible that prolonged heavy alcohol 
use increases the influence of negative affect? As noted above, 
research in humans suggests that the immediate relief from 
negative emotions provided by alcohol consumption increases 
the likelihood of repeated pairings. Animals that are selectively 
bred to prefer alcohol grant researchers the ability to evaluate 
this premise and manipulate factors, such as neurotransmitter 
systems, which facilitate this association. The use of selectively 
bred animals is recommended when investigating the interaction 
of two traits (alcohol preference and negative urgency).
Second, it enables the testing of novel compounds and their 
ability to reduce negative urgency-like behaviors, which, if 
successful, could then be applied and tested in clinical models. 
This treatment may be pharmacological, as in a drug purported 
to reduce anxiety (targeting the affective aspect), or behavioral, 
such as training the subject to reduce excessive lever pressing in 
times of stress (targeting the rash behavior aspect). Examining 
these treatments in animals first allows for testing of initial 
feasibility, safety, and effectiveness prior to implementing 
such interventions in humans. These treatments may produce 
objective, quantifiable outcomes that can then be administered 
in a clinical setting. Given the demonstrated influence of negative 
urgency on increased alcohol consumption in alcohol use disorder 
populations and the increased elucidation of neural mechanisms 
underlying this association, developing novel therapeutic 
targets through animal models should constitute the next step 
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toward more efficacious treatment options. Upon design of a 
translational, externally valid animal model, there are numerous 
possible targets of investigation. In particular, administration of 
agents designed to boost 5HT availability, specifically in the PFC, 
could generate a cascading effect downstream in the DA system 
of the OFC–amygdala circuit. Alternatively, increasing levels of 
GABA in the dlPFC may heighten the ability of this region to 
function efficiently, alleviating the heavy cognitive load required 
by subjects with high negative urgency to inhibit behavior.
Translation to animal models in this way has provided 
greater understanding of neural correlates of behavior in several 
domains. For instance, the symptoms of bipolar disorder are often 
alleviated through lithium administration, which also serves to 
decrease incidents of suicidal behavior (161–163). Valproate, an 
alternate method for bipolar disorder treatment, is also efficacious 
in relieving symptoms, but has no effect on suicidal behavior 
(164). A study evaluating the effects of these drugs on impulsivity 
using the delay discounting task revealed that lithium was more 
effective at reducing impulsive behavior in that paradigm, 
which may underlie the decrease in suicide attempts in that 
population (165). Models of Parkinson’s and Alzheimer’s disease 
have provided valuable information on the neural deterioration 
or malfunctioning that accompany the symptoms of those 
disorders (166–170). Animal models of depression have helped 
identify brain network and neurotransmitter systems associated 
with negative affect (171–174). One of the most useful tools of 
the animal model is to administer pharmacological therapies to 
attempt to identify what neurobiological mechanisms underlie 
symptoms and behavior.
Third, it allows for the manipulation of negative urgency in 
human studies and how changing the immediate expression of 
the trait can be clinically applied. Such studies would help test the 
viability of potential interventions in changing negative urgency 
in the human laboratory. It would also allow the use of a behavioral 
task of negative urgency as an objective marker of change for 
clinical trials of negative-urgency-based interventions, avoiding 
limitations related to self-report, as described above. Therefore, 
it is clear that the use of objective translational paradigms of 
negative urgency would be conducive to advancing research 
concerning the treatment of addictive disorders, as well as other 
comorbid disorders related to negative urgency.
CONCLUSIONS, LIMITATIONS, AND 
SUGGESTIONS FOR FUTURE WORK
We propose two important gaps in research on negative urgency 
that should be filled as next steps in the long-term goal of 
intervening on negative urgency. First, existing translational 
approaches for negative urgency only assess negative affect 
or impulsive behavior, but not both. We suggest that only by 
combining these two aspects of negative urgency into one model 
can we increase the validity of the model in both animal and 
human subjects. There is still some work to do to figure out the 
most valid way to create such a translational model. In devising a 
translatable method to accurately evaluate negative urgency, and 
more importantly to develop a model that is sensitive enough to 
detect changes in behavior, investigators should seek to preserve 
as many aspects of validity as possible (Table 1). Of course, other 
potential methods could be developed, but should meet minimal 
validity criteria. Importantly, many of the methods of inducing 
negative emotions in humans have limited translatability, 
hindering the design of a truly translational task. The reward 
omission task may be a prime place to start to induce negative 
emotion across human and animal models. However, other 
approaches to induce negative affect translationally may need 
to be species specific. For example, food restriction might be 
effective and useful in animal models, but these methods have 
feasibility and ethical restraints in human work. In an animal 
model, acute restraint stress, food deprivation, and foot shock are 
demonstrably effective at inciting negative affect; however, these 
methods may lead to increased corticotrophin levels or persistent 
depressive-like symptoms, so exposure should be minimal. Any 
combination of these methods should be thoroughly vetted 
and rigorously tested to establish both construct and predictive 
validity. In contrast, several of the impulsivity methods are 
highly translatable (Table 1) and serve as good starting points 
in designing a new model. Of these impulsivity tasks, the delay 
discounting task would be the most effective for use of cognitive 
impulsivity inquiries, while the Go/No-Go task would be most 
informative for measures of motor impulsivity.
One limitation of investigations of negative urgency is the 
difficulty in parsing specific emotional reactions for evaluation. 
There is inherently a great deal of overlap in experience of 
emotion; anger, fear, and sadness often co-occur and the neural 
underpinnings of singular emotions are highly interconnected. 
An excellent review from Price (175) on the neurocircuitry of 
mood disorders describes this phenomenon very succinctly, 
identifying several structures, including the primary structures 
of the limbic system and hippocampal regions, which contribute 
to various emotions and how those structures interconnect. 
Although the ability to efficiently unravel such closely related 
emotions (sadness, stress, etc). would be ideal, it has not yet been 
successfully accomplished and negative urgency has been shown 
and theorized to relate to multiple different negative emotions, 
including sadness, stress, and anger. Unfortunately, the inability 
to untangle specific emotions may hinder the ability of animal 
research to completely model the human experience.
Another important caveat of developing a translational model 
of negative urgency is the distinction between state and trait 
behavior, which show little overlap (46). This might limit the 
feasibility of developing a translational model. Current self-report 
evaluations of negative urgency in humans are effective at assessing 
trait levels of negative urgency; a similar trait-like construct may 
be modeled in animals through selective breeding. For example, 
the high alcohol-preferring mouse lines have demonstrated higher 
impulsive behavior in the delay discounting task (76), making 
them an ideal model for investigations of trait impulsivity. State 
behavior is successfully measured in both human and animal 
models, allowing for the potential of strong concordance between 
these groups. Although state and trait approaches do not overlap 
strongly, researchers propose that increased overlap would likely 
occur through increased specificity in the measures (46). For 
example, performing a behavioral task under a negative emotional 
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state would theoretically lead to larger correlations between the 
state measure and the trait of negative urgency.
Second, research has yet to examine identified human neural 
and genetic correlates of negative affect in animal models. There 
are numerous avenues for exploration that are well supported 
in the field and should be manipulated in animal models to test 
their potential treatment value. Abundant research implicates 
dysfunction of the serotonin and dopamine systems in regulation 
of the OFC–amygdala circuit may contribute to behavioral 
disinhibition during negative emotional states. There is also 
evidence of the contribution of GABA unavailability in the PFC, 
which may account for the excessive activation during response 
inhibition in subjects high in negative urgency. Identifying agents 
that efficiently reduce impulsive behavior during negative urgency 
in an animal model provides a basis for potential applications in 
a clinical setting. Future work should aim to further elucidate the 
influence of the OFC–amygdala circuit (emotional processing) and 
regions of the prefrontal cortex (behavioral control) in negative 
urgency. Novel pharmacological treatments can be discovered 
through manipulation strategies only available in animal models, 
which can then be applied in a clinical setting. It should be noted 
that although several lines of research have identified rodent brain 
regions as homologous to the human prefrontal cortex regions, 
there is no definitive nomenclature that accurately confirms these 
regions (169), which may limit translatability of neural data across 
preclinical and clinical models, although this type of work has 
been successful in related disorders (for review, see Ref. 93).
In conclusion, we suggest that future studies should seek to devise 
and test a valid translational model of negative urgency that is easily 
administered in both animals and human subjects. We hope that our 
review not only answers some questions about how to do this, but 
also creates new questions that can improve and advance this work 
more in the future. The long-term goal of such work will be to bring 
together basic research on negative urgency and clinical practice of 
addiction medicine, for more effective prevention, treatment, and 
rehabilitation of addictive disorders. We suggest that development 
of this model will allow for determination of prime neurological and 
physiological treatment targets, the testing of treatment effectiveness 
in the preclinical and the clinical laboratory, and, ultimately, 
improvement in negative-urgency-related treatment response and 
effectiveness. Given that negative urgency is a transdiagnostic risk 
factor that impedes treatment success, the impact of this work could 
be large in reducing client suffering and societal costs.
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